Meletios-Athanasios Dimopoulos

Differential donor‐, cell type‐ and drug‐specific molecular responses to therapeutic proteasome inhibitors in Multiple Myeloma patients and cells

Introduction: Purpose of the study: Proteasome over‐activation represents a hallmark of several advanced tumors and thus, its selective inhibition provides a promising anti‐tumor the...

Ourania Tsitsilonis ;

Herman Overkleeft ;

Leonidas Alexopoulos ;

Ioannis Trougakos ;

Meletios-Athanasios Dimopoulos ;

Eleni-Dimitra Papanagnou ;

Efstathios Kastritis ;

Aikaterini Skorda ;

Aimilia Sklirou ;

Evangelos Terpos ;

10/22/2019

Depth of Response of Isatuximab (Isa) plus Carfilzomib (K) and Dexamethasone (d) in Relapsed Multiple Myeloma: IKEMA Updated Analysis

Introduction:Achievement of minimal residual disease negativity (MRD‚Äì) status in multiple myeloma (MM) is associated with improved progression-free survival (PFS) and overall survival. ...

Nelson Castro ;

Tomas Pika ;

Javier De la Rubia ;

Angelo Maiolino ;

Anthony Reiman ;

Thomas G. Martin III, MD;

Sylvia Marion ;

Joseph Mikhael , MD, MEd, FRCPC;

Roman Hajek ;

Sosana Delimpasi ;

Joaquin Martinez-Lopez ;

Sandrine Mace ;

Phillippe Moreau ;

Kwee Yong ;

Meletios-Athanasios Dimopoulos ;

France Casca ;

Marie-Laure Risse ;

Bradle Augustson ;

11/04/2022

Updated Progression-free Survival (PFS) and Depth of Response in IKEMA, A Randomized Phase 3 Trial of Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) vs Kd in Relapsed Multiple Myeloma (MM)

Introduction:The anti-CD38 antibody Isa in combination with Kd is approved in various countries for patients (pts) with relapsed MM after ‚â•1 prior therapy, based on primary interim anal...

Thomas G. Martin III, MD;

Joseph Mikhael , MD, MEd, FRCPC;

Roman Hajek ;

Sandrine Mace ;

Phillippe Moreau ;

Kwee Yong ;

Marcelo Capra ;

Thierry Facon ;

France Casca ;

Marie-Laure Risse ;

Meletios-Athanasios Dimopoulos ;

11/04/2022

Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/ Relapsed or Refractory Multiple Myeloma

Purpose of the Study: Carfilzomib (K), an irreversible proteasome inhibitor, is approved for the treatment of patients (pts) with relapsed or refractory  multiple  myeloma &nbsp...

Xavier Leleu ;

Meral Beksac ;

Maria-Victoria Mateos ;

Ludek Pour ;

Katja Weisel ;

Daniel Coriu ;

Mihaela Obreja ;

Amanda Goldrick ;

Meletios-Athanasios Dimopoulos ;

10/23/2019

Patient-Reported Outcomes from Patients with Waldenström Macroglobulinemia Treated with Ibrutinib-Rituximab: Results from iNNOVATE Study

Purpose of the Study: For patients with Waldenström macroglobuli- nemia (WM), anemia and fatigue can impair quality of life. Ibrutinib is the only once-daily inhibitor of Brutons tyrosine...

Bernhard Hauns ;

Christian Buske ;

Steve Treon , MD, PhD, FRCP, FACP;

Veronique Leblond ;

Alessandra Tedeschi ;

Judith Trotman ;

Ramón García-Sanz ;

David Macdonald ;

Meletios-Athanasios Dimopoulos ;

Beatrice Mahe ;

Charles Herbaux ;

Leonard Heffner ;

Marzia Varettoni ;

M. Lia Palomba ;

Constantine S. Tam ;

Chaim Shustik ;

Jeffrey Matous , MD;

Efstathios Kastritis ;

Jianling Li ;

Erik G. Poulsen ;

10/23/2019

Patient-Reported Outcomes from Patients with Waldenström Macroglobulinemia Treated with Ibrutinib-Rituximab: Results from iNNOVATE Study

Purpose of the Study: For patients with Waldenström macroglobuli- nemia (WM), anemia and fatigue can impair quality of life. Ibrutinib is the only once-daily inhibitor of Brutons tyrosine...

Erik G. Poulsen ;

Bernhard Hauns ;

Christian Buske ;

Steve Treon , MD, PhD, FRCP, FACP;

Veronique Leblond ;

Alessandra Tedeschi ;

Judith Trotman ;

Ramón García-Sanz ;

David Macdonald ;

Meletios-Athanasios Dimopoulos ;

Beatrice Mahe ;

Charles Herbaux ;

Leonard Heffner ;

Marzia Varettoni ;

M. Lia Palomba ;

Constantine S. Tam ;

Chaim Shustik ;

Jeffrey Matous , MD;

Efstathios Kastritis ;

Jianling Li ;

10/23/2019

Conference Coverage

Advancing Treatment Options for High-Risk Multiple Myeloma

10/02/2024

Meletios-Athanasios Dimopoulos ;

Discover how the addition of daratumumab to standard treatment improves outcomes for patients with high-risk cytogenetic abnormalities in multiple myeloma according to a SOHO 2024 presenter.

Discover how the addition of...

10/02/2024

First Report Managed Care